Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with Rare Monoclonal Gammopathies of Renal Significance
Latest Information Update: 21 Jan 2025
Price :
$35 *
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary)
- Indications Glomerulonephritis
- Focus Therapeutic Use
- 21 Jan 2025 New trial record